Longevity News

Novel antimicrobial peptides derived from Brevibacillus laterosporus DSM 25 targeting MurT ligase exhibit broad-spectrum activity against drug-resistant pathogens

Source: Nature - Biotechnology • Published: 31 Aug 2026, 00:00

Novel antimicrobial peptides derived from Brevibacillus laterosporus DSM 25 targeting MurT ligase exhibit broad-spectrum activity against drug-resistant pathogens

Reports discovery and initial characterization of two antimicrobial peptides from a bacterial proteome that bind MurT ligase and kill drug-resistant bacteria in vitro.

Key Takeaways
  • It is citable and carries a permanent DOI
  • This version is subject to further edits and will be replaced automatically by the final Version of Record
  • In this context, antimicrobial peptides (AMPs) have emerged as strong therapeutic candidates
Read Original Source

Continue exploring

Related longevity signals

Nature - BiotechnologyTIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemiaCovers a TIM3-targeted nanoformulation that co-delivers venetoclax and NK-engaging antibodies to tackle venetoclax-resistant acute myeloid leukemia and reshape the tumor immune microenvironment.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Fight Aging!Physical Activity Correlates with Reductions in TMAO, Inflammation, and Harmful Bone RemodelingPhysical activity piece previewing research on how habitual exercise links to gut-driven inflammation and bone aging mechanisms. It invites readers curious about molecular pathways behind exercise’s skeletal benefits.Longevity TechnologyNRG Therapeutics shows promising lab results for new ALS drug candidateNRG Therapeutics’ preclinical report invites readers to examine lab and mechanistic data for a novel ALS drug candidate and its next-stage plans.